<DOC>
	<DOCNO>NCT01482182</DOCNO>
	<brief_summary>In prospective study , investigator evaluate compare usefulness functional volumetric information obtain 18F-FDG PET MRI palliative chemotherapy aim predict tumor response prognosis patient advance Non-small Cell Lung Cancer ( NSCLC ) .</brief_summary>
	<brief_title>Predictive Value FDG PET/CT , DWI DCE-MRI Scans Non-small Cell Lung Cancer Patients Receiving Chemotherapy</brief_title>
	<detailed_description>Study cohort undergo PET/CT MRI scan prior chemotherapy first chemotherapy cycle . MRI scan include DCE-MRI DWI . The following parameter calculate use value : 1 . Metabolic parameter FDG-PET A. SUV change ratio ( SCR ) = SUVpost/SUVpre B. MTV change ratio ( VCR ) = MTVpost/pre C. TLG change ratio = SCR X VCR 2 . Perfusion parameter DCE-MRI A. Kep B. K-trans C. 3 . Diffusion parameter DWI A . Mean ADC B. fDM</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically proven NSCLC Newly diagnose Stage stage IV Participant consider chemotherapy EGFR TKI first line therapy At least one measurable primary intrathoracic lesion &gt; = 2cm , accord RECIST Performance status 0 2 ECOG scale Age 18 year older Able tolerable PET/CT MRI imaging require protocol Able give studyspecific inform consent Pure bronchioloalveolar cell carcinoma histology Thoracic radiotherapy , lung surgery chemotherapy within three month prior inclusion study Poorly control diabetes Prior malignancy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Diffusion-weighted MRI</keyword>
	<keyword>18F-FDG PET</keyword>
	<keyword>Treatment response</keyword>
	<keyword>Prognosis</keyword>
</DOC>